The complement system in COVID-19: friend and foe?

Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19-related morbidity and mortality have been attributed to an exaggerated immune response. The role of compl...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:JCI insight Ročník 5; číslo 15
Hlavní autori: Java, Anuja, Apicelli, Anthony J, Liszewski, M Kathryn, Coler-Reilly, Ariella, Atkinson, John P, Kim, Alfred Hj, Kulkarni, Hrishikesh S
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Society for Clinical Investigation 06.08.2020
Predmet:
Betacoronavirus - pathogenicity
Betacoronavirus - physiology
Blood Coagulation
Cell activation
Clinical trials
Complement activation
Complement Activation - immunology
Complement inhibitors
Complement system
Coronaviridae
Coronavirus Infections - blood
Coronavirus Infections - immunology
Coronaviruses
COVID-19
Endothelial Cells - virology
Humans
Immune response
Middle East respiratory syndrome
Morbidity
Neutrophilia
Pandemics
Pneumonia, Viral - blood
Pneumonia, Viral - immunology
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Viral infections
Viruses
United States > US
Italy
China
ISSN:2379-3708, 2379-3708
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a global pandemic and a disruptive health crisis. COVID-19-related morbidity and mortality have been attributed to an exaggerated immune response. The role of complement activation and its contribution to illness severity is being increasingly recognized. Here, we summarize current knowledge about the interaction of coronaviruses with the complement system. We posit that (a) coronaviruses activate multiple complement pathways; (b) severe COVID-19 clinical features often resemble complementopathies; (c) the combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19; (d) a subset of patients with COVID-19 may have a genetic predisposition associated with complement dysregulation; and (e) these observations create a basis for clinical trials of complement inhibitors in life-threatening illness.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Authorship note: AHJK and HSK are co–senior authors and contributed equally to this work.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.140711